Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report issued on Wednesday. The brokerage set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Price Performance

NASDAQ:RKDA opened at $4.34 on Wednesday. Arcadia Biosciences has a one year low of $1.85 and a one year high of $5.34. The company has a market cap of $5.92 million, a PE ratio of -0.84 and a beta of 1.34. The firm has a 50-day moving average of $3.06 and a 200-day moving average of $2.85.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $0.95 million. During the same period in the prior year, the firm posted ($2.64) earnings per share. On average, equities research analysts expect that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.